A Critique of 25 Years of Research Which Culminated in the Successful Therapy of Periodontal Disease with Coenzyme Q10.
スポンサーリンク
概要
- 論文の詳細を見る
Periodontal disease involves in inflammation of tissues which support the teeth, and in primarily caused by the accumulating bacterial plaque on the teeth. The extraction of teeth is the end stage. Current statistics show that about 60% of young adults and 80% of adults in the U.S. have periodontal disease, i. e., this disease is not limited just to the older generations.<BR>The initially available Coenzyme Q<SUB>7</SUB> (CoQ<SUB>7</SUB>) was clinically found to improve therapeutically severe and destructive periodontal disease. CoQ<SUB>7</SUB> had been found to show 80-100% of the activity of Coenzyme Q<SUB>10</SUB> (CoQ<SUB>10</SUB>) for NADH-oxidase.<BR>The partially synthetic hexahydro-CoQ<SUB>4</SUB> (H<SUB>6</SUB>CoQ<SUB>4</SUB>) became abundantly available for clinical research, although it showed only 10-25% of the activity of CoQ<SUB>10</SUB> for NADH-oxidase. Over ca. five years, H<SUB>6</SUB>CoQ<SUB>4</SUB> was clinically tested, including a double-blind trial, for therapy of periodontal disease, and was found to cause such extraordinary healing that H<SUB>6</SUB>CoQ<SUB>4</SUB> was considered as conjunctive therapy for ordinary dental practice.<BR>It had been determined that there was a statistically significant deficiency of CoQ<SUB>10</SUB>-enzyme activity in gingival biopsies from patients with periodontal disease in comparison to control. In due time, CoQ<SUB>10</SUB> became available for clinical studies on therapy of periodontal disease. After an open trial of treating periodontal disease with CoQ<SUB>10</SUB>, which was interpreted to the effect that healing was--"dramatically accelerated"--and was--"very impressive", a successful double-blind trial was conducted with capsules of CoQ<SUB>10</SUB> and a matching placebo.<BR>Subsequent trials were concluded with the observation that--"CoQ<SUB>10</SUB> could well become an essential modality of prevention and treatment of periodontal disease".<BR>These open and double-blind trials were largely based upon criteria of periodontal score, tooth mobility, gingival index and pocket depth. Recently, the bleeding index was another criterion of therapy, and the result was positive.<BR>Currently, the reduction of subgingival microorganisms has been recorded, and concomitantly, it was recorded that CoQ<SUB>10</SUB> increased the levels of the T4/T8 ratio and that of IgG.<BR>The repeatedly demonstrated successful therapy with CoQ<SUB>10</SUB> of periodontal disease is evident from several criteria showing reduced disease, from criteria of an improved immune system, and restored periods of natural prevention of disease.<BR>CoQ<SUB>10</SUB> is, therefore, recommended for both prophylactic and therapeutic treatment of periodontal disease.
- 有限責任中間法人 日本口腔衛生学会の論文
有限責任中間法人 日本口腔衛生学会 | 論文
- 水銀中毒に関する研究 (Hg. series No. 11) : 歯科医業従事者の水銀吸収について
- 新しい齲蝕活動性試験法に関する研究 : II. 試験液S-3105の臨床応用について
- 口腔連鎖球菌由来の菌体外プロテアーゼについて
- Streptomyces globisporus由来の溶菌酵素活性に及ぼすsodium N-lauroyl sarcosinateならびにsodium lauryl sulfateの効果
- Streptomyces globisporus 1829株由来の溶菌酵素の人, 牛エナメル質及びハイドロオキシアパタイトへの吸着